The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Interstitial Lung Disease: A Review
Abstract
Importance: Interstitial lung disease (ILD) consists of a group of pulmonary disorders characterized by inflammation and/or fibrosis of the lung parenchyma associated with progressive dyspnea that frequently results in end-stage respiratory failure. In the US, ILD affects approximately 650 000 people and causes approximately 25 000 to 30 000 deaths per year. Observations: The most common forms of ILD are idiopathic pulmonary fibrosis (IPF), which accounts for approximately one-third of all cases of ILD, hypersensitivity pneumonitis, accounting for 15% of ILD cases, and connective tissue disease (CTD), accounting for 25% of ILD cases. ILD typically presents with dyspnea on exertion. Approximately 30% of patients with ILD report cough. Thoracic computed tomography is approximately 91% sensitive and 71% specific for diagnosing subtypes of ILDs such as IPF. Physiologic assessment provides important prognostic information. A 5% decline in forced vital capacity (FVC) over 12 months is associated with an approximately 2-fold increase in mortality compared with no change in FVC. Antifibrotic therapy with nintedanib or pirfenidone slows annual FVC decline by approximately 44% to 57% in individuals with IPF, scleroderma associated ILD, and in those with progressive pulmonary fibrosis of any cause. For connective tissue disease–associated ILD, immunomodulatory therapy, such as tocilizumab, rituximab, and mycophenolate mofetil, may slow decline or even improve FVC at 12-month follow-up. Structured exercise therapy reduces symptoms and improves 6-minute walk test distance in individuals with dyspnea. Oxygen reduces symptoms and improves quality of life in individuals with ILD who desaturate below 88% on a 6-minute walk test. Lung transplant may improve symptoms and resolve respiratory failure in patients with end-stage ILD. After lung transplant, patients with ILD have a median survival of 5.2 to 6.7 years compared with a median survival of less than 2 years in patients with advanced ILD who do not undergo lung transplant. Up to 85% of individuals with end-stage fibrotic ILD develop pulmonary hypertension. In these patients, treatment with inhaled treprostinil improves walking distance and respiratory symptoms. Conclusions and Relevance: Interstitial lung disease typically presents with dyspnea on exertion and can progress to respiratory failure. First-line therapy includes nintedanib or pirfenidone for IPF and mycophenolate mofetil for ILD due to connective tissue disease. Lung transplant should be considered for patients with advanced ILD. In patients with ILD, exercise training improves 6-minute walk test distance and quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Travis, W. D., Costabel, U., Hansell, D. M., King, T. E., Lynch, D. A., Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201308-1483st · Cited by 4,290
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Raghu, G., Remy-Jardin, M., Richeldi, L., Thomson, C. C., Inoue, Y., Johkoh, T., Kreuter, M., Lynch, D. A., Maher, T. M., Martinez, F. J., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202202-0399st · Cited by 2,957
Self-citation2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano-Subias, P., Ferrari, P., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.00879-2022 · Cited by 2,247
Cyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
Nintedanib for systemic sclerosis–associated interstitial lung disease
Distler, O., Highland, K. B., Gahlemann, M., Azuma, A., Fischer, A., Mayes, M. D., Raghu, G., Sauter, W., Girard, M., Alves, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903076 · Cited by 1,647
Self-citationPrednisone, Azathioprine, and N -Acetylcysteine for Pulmonary Fibrosis
The Idiopathic Pulmonary Fibrosis Clinical Research Network (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113354 · Cited by 1,621
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
Collard, H. R., Ryerson, C. J., Corte, T. J., Jenkins, G., Kondoh, Y., Lederer, D. J., Lee, J. S., Maher, T. M., Wells, A. U., Antoniou, K. M., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201604-0801ci · Cited by 1,444
Self-citationA Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis
Ley, B., Ryerson, C. J., Vittinghoff, E., Ryu, J. H., Tomassetti, S., Lee, J. S., Poletti, V., Buccioli, M., Elicker, B. M., Jones, K. D., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-10-201205150-00004 · Cited by 1,308
Chambers, D. C., Cherikh, W. S., Harhay, M. O., Hayes, D., Hsich, E., Khush, K. K., Meiser, B., Potena, L., Rossano, J. W., Toll, A. E., et al. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.08.001 · Cited by 1,269
Tashkin, D. P., Roth, M. D., Clements, P. J., Furst, D. E., Khanna, D., Kleerup, E. C., Goldin, J., Arriola, E., Volkmann, E. R., Kafaja, S., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30152-7 · Cited by 1,078
Raghu, G., Remy-Jardin, M., Ryerson, C. J., Myers, J. L., Kreuter, M., Vasakova, M., Bargagli, E., Chung, J. H., Collins, B. F., Bendstrup, E., et al. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202005-2032st · Cited by 1,047
Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review
Hutchinson, J., Fogarty, A., Hubbard, R., & McKeever, T. (2015) · European Respiratory Journal · doi:10.1183/09031936.00185114 · Cited by 913
Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.005 · Cited by 821
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis
Fingerlin, T. E., Murphy, E., Zhang, W., Peljto, A. L., Brown, K. K., Steele, M. P., Loyd, J. E., Cosgrove, G. P., Lynch, D., Groshong, S., et al. (2013) · Nature Genetics · doi:10.1038/ng.2609 · Cited by 809
Self-citationAcute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Khanna, D., Denton, C. P., Jahreis, A., van Laar, J. M., Frech, T. M., Anderson, M. E., Baron, M., Chung, L., Fierlbeck, G., Lakshminarayanan, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00232-4 · Cited by 683
Idiopathic Interstitial Pneumonia: What Is the Effect of a Multidisciplinary Approach to Diagnosis?
Flaherty, K. R., King, T. E., Raghu, G., Lynch, J. P., Colby, T. V., Travis, W. D., Gross, B. H., Kazerooni, E. A., Toews, G. B., Long, Q., et al. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200402-147oc · Cited by 673
Histopathologic Variability in Usual and Nonspecific Interstitial Pneumonias
FLAHERTY, K. R., TRAVIS, W. D., COLBY, T. V., TOEWS, G. B., KAZEROONI, E. A., GROSS, B. H., JAIN, A., STRAWDERMAN, R. L., FLINT, A., LYNCH, J. P., et al. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.9.2103074 · Cited by 665
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
Khanna, D., Lin, C. J. F., Furst, D. E., Goldin, J., Kim, G., Kuwana, M., Allanore, Y., Matucci-Cerinic, M., Distler, O., Shima, Y., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30318-0 · Cited by 662
A Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary Fibrosis
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002110 · Cited by 634
Maher, T. M., Corte, T. J., Fischer, A., Kreuter, M., Lederer, D. J., Molina-Molina, M., Axmann, J., Kirchgaessler, K.-U., Samara, K., Gilberg, F., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30341-8 · Cited by 629
Self-citationGlobal incidence and prevalence of idiopathic pulmonary fibrosis
Maher, T. M., Bendstrup, E., Dron, L., Langley, J., Smith, G., Khalid, J. M., Patel, H., & Kreuter, M. (2021) · Respiratory Research · doi:10.1186/s12931-021-01791-z · Cited by 612
Self-citationWells, A. U., Flaherty, K. R., Brown, K. K., Inoue, Y., Devaraj, A., Richeldi, L., Moua, T., Crestani, B., Wuyts, W. A., Stowasser, S., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30036-9 · Cited by 569
Self-citationTreatment of Idiopathic Pulmonary Fibrosis With Ambrisentan: A Parallel, Randomized Trial
Raghu, G., Behr, J., Brown, K. K., Egan, J. J., Kawut, S. M., Flaherty, K. R., Martinez, F. J., Nathan, S. D., Wells, A. U., Collard, H. R., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-9-201305070-00003 · Cited by 553
King, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Behr, J., Prasse, A., Kreuter, M., Johow, J., Rabe, K. F., Bonella, F., Bonnet, R., Grohe, C., Held, M., Wilkens, H., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30554-3 · Cited by 522
MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
Juge, P.-A., Lee, J. S., Ebstein, E., Furukawa, H., Dobrinskikh, E., Gazal, S., Kannengiesser, C., Ottaviani, S., Oka, S., Tohma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801562 · Cited by 520
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., du Bois, R. M., Fagan, E. A., Fishman, R. S., Glaspole, I., Glassberg, M. K., Lancaster, L., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00026-2015 · Cited by 468
A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis
Noth, I., Anstrom, K. J., Calvert, S. B., de Andrade, J., Flaherty, K. R., Glazer, C., Kaner, R. J., & Olman, M. A. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201202-0314oc · Cited by 463
Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review
Raghu, G., Amatto, V. C., Behr, J., & Stowasser, S. (2015) · European Respiratory Journal · doi:10.1183/13993003.02316-2014 · Cited by 463
Zhang, P., Li, J., Liu, H., Han, N., Ju, J., Kou, Y., Chen, L., Jiang, M., Pan, F., Zheng, Y., et al. (2020) · Bone Research · doi:10.1038/s41413-020-0084-5 · Cited by 440
Hutchinson, J. P., Fogarty, A. W., McKeever, T. M., & Hubbard, R. B. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201508-1632oc · Cited by 440
Drug-Induced Interstitial Lung Disease: A Systematic Review
Skeoch, S., Weatherley, N., Swift, A. J., Oldroyd, A., Johns, C., Hayton, C., Giollo, A., Wild, J. M., Waterton, J. C., Buch, M., et al. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7100356 · Cited by 422
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Delaunay, M., Cadranel, J., Lusque, A., Meyer, N., Gounant, V., Moro-Sibilot, D., Michot, J.-M., Raimbourg, J., Girard, N., Guisier, F., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00050-2017 · Cited by 412
Troy, L. K., Grainge, C., Corte, T. J., Williamson, J. P., Vallely, M. P., Cooper, W. A., Mahar, A., Myers, J. L., Lai, S., Mulyadi, E., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30342-x · Cited by 396
Imatinib Treatment for Idiopathic Pulmonary Fibrosis: Randomized Placebo-controlled Trial Results
Daniels, C. E., Lasky, J. A., Limper, A. H., Mieras, K., Gabor, E., & Schroeder, D. R. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0964oc · Cited by 373
Zappala, C. J., Latsi, P. I., Nicholson, A. G., Colby, T. V., Cramer, D., Renzoni, E. A., Hansell, D. M., du Bois, R. M., & Wells, A. U. (2010) · European Respiratory Journal · doi:10.1183/09031936.00155108 · Cited by 372
Opiate Therapy in Chronic Cough
Morice, A. H., Menon, M. S., Mulrennan, S. A., Everett, C. F., Wright, C., Jackson, J., & Thompson, R. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200607-892oc · Cited by 363
Genome-wide association study of susceptibility to idiopathic pulmonary fibrosis
Allen, R. J., Guillen-Guio, B., Oldham, J. M., Ma, S.-F., Dressen, A., Paynton, M. L., Kraven, L. M., Obeidat, M., Li, X., Ng, M., et al. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201905-1017oc · Cited by 329
Self-citationOccupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis
Hubbard, R., Lewis, S., Richards, K., Johnston, I., & Britton, J. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90465-1 · Cited by 318
Prevalence and prognosis of unclassifiable interstitial lung disease
Ryerson, C. J., Urbania, T. H., Richeldi, L., Mooney, J. J., Lee, J. S., Jones, K. D., Elicker, B. M., Koth, L. L., King, T. E., Wolters, P. J., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00131912 · Cited by 310
Maher, T. M., Tudor, V. A., Saunders, P., Gibbons, M. A., Fletcher, S. V., Denton, C. P., Hoyles, R. K., Parfrey, H., Renzoni, E. A., Kokosi, M., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00359-9 · Cited by 290
Self-citationSurvival in adult lung transplantation: where are we in 2020?
Bos, S., Vos, R., Van Raemdonck, D. E., & Verleden, G. M. (2020) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000753 · Cited by 281
Ebata, S., Yoshizaki, A., Oba, K., Kashiwabara, K., Ueda, K., Uemura, Y., Watadani, T., Fukasawa, T., Miura, S., Yoshizaki-Ogawa, A., et al. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00107-7 · Cited by 274
Nathan, S. D., Behr, J., Collard, H. R., Cottin, V., Hoeper, M. M., Martinez, F. J., Corte, T. J., Keogh, A. M., Leuchte, H., Mogulkoc, N., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30250-4 · Cited by 253
Visca, D., Mori, L., Tsipouri, V., Fleming, S., Firouzi, A., Bonini, M., Pavitt, M. J., Alfieri, V., Canu, S., Bonifazi, M., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30289-3 · Cited by 235
Self-citationJo, H. E., Glaspole, I., Grainge, C., Goh, N., Hopkins, P. M. A., Moodley, Y., Reynolds, P. N., Chapman, S., Walters, E. H., Zappala, C., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.01592-2016 · Cited by 233
Bosentan in Pulmonary Hypertension Associated with Fibrotic Idiopathic Interstitial Pneumonia
Corte, T. J., Keir, G. J., Dimopoulos, K., Howard, L., Corris, P. A., Parfitt, L., Foley, C., Yanez-Lopez, M., Babalis, D., Marino, P., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201403-0446oc · Cited by 226
Self-citationHighland, K. B., Distler, O., Kuwana, M., Allanore, Y., Assassi, S., Azuma, A., Bourdin, A., Denton, C. P., Distler, J. H. W., Hoffmann-Vold, A. M., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30330-1 · Cited by 217
Self-citationSolomon, J. J., Danoff, S. K., Woodhead, F. A., Hurwitz, S., Maurer, R., Glaspole, I., Dellaripa, P. F., Gooptu, B., Vassallo, R., Cox, P. G., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00260-0 · Cited by 216
Self-citationFernández Pérez, E. R., Kong, A. M., Raimundo, K., Koelsch, T. L., Kulkarni, R., & Cole, A. L. (2018) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201704-288oc · Cited by 213
Lancaster, L., Crestani, B., Hernandez, P., Inoue, Y., Wachtlin, D., Loaiza, L., Quaresma, M., Stowasser, S., & Richeldi, L. (2019) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2018-000397 · Cited by 209
Paterniti, M. O., Bi, Y., Rekić, D., Wang, Y., Karimi-Shah, B. A., & Chowdhury, B. A. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201606-458oc · Cited by 194
Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis
Russell, A.-M., Adamali, H., Molyneaux, P. L., Lukey, P. T., Marshall, R. P., Renzoni, E. A., Wells, A. U., & Maher, T. M. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201511-2152oc · Cited by 178
Self-citationThe role of infection in the pathogenesis of idiopathic pulmonary fibrosis
Molyneaux, P. L., & Maher, T. M. (2013) · European Respiratory Review · doi:10.1183/09059180.00000713 · Cited by 171
Self-citationRaghu, G., Montesi, S. B., Silver, R. M., Hossain, T., Macrea, M., Herman, D., Barnes, H., Adegunsoye, A., Azuma, A., Chung, L., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202306-1113st · Cited by 169
Conti, S., Harari, S. A., Caminati, A., Zanobetti, A., Schwartz, J. D., Bertazzi, P. A., Cesana, G., & Madotto, F. (2018) · European Respiratory Journal · doi:10.1183/13993003.00397-2017 · Cited by 168
OPTN/SRTR 2018 Annual Data Report: Lung
Valapour, M., Lehr, C. J., Skeans, M. A., Smith, J. M., Uccellini, K., Goff, R., Foutz, J., Israni, A. K., Snyder, J. J., & Kasiske, B. L. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15677 · Cited by 168
Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction
Raghu, G., Nathan, S. D., Behr, J., Brown, K. K., Egan, J. J., Kawut, S. M., Flaherty, K. R., Martinez, F. J., Wells, A. U., Shao, L., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01537-2014 · Cited by 163
Validation of Proposed Criteria for Progressive Pulmonary Fibrosis
Pugashetti, J. V., Adegunsoye, A., Wu, Z., Lee, C. T., Srikrishnan, A., Ghodrati, S., Vo, V., Renzoni, E. A., Wells, A. U., Garcia, C. K., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202201-0124oc · Cited by 162
Behr, J., Nathan, S. D., Wuyts, W. A., Moğulkoç, N., Bouros, D. E., Antoniou, K. M., Guiot, J., Kramer, M. R., Kirchgaessler, K.-U., Bengus, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30356-8 · Cited by 150
Lung function trajectory in progressive fibrosing interstitial lung disease
Oldham, J. M., Lee, C. T., Wu, Z., Bowman, W. S., Pugashetti, J. V., Đao, N. H., Tonkin, J., Seede, H., Echt, G., Adegunsoye, A., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.01396-2021 · Cited by 149
Self-citationMaher, T. M., Ford, P., Brown, K. K., Costabel, U., Cottin, V., Danoff, S. K., Groenveld, I., Helmer, E., Jenkins, R. G., Milner, J., et al. (2023) · JAMA · doi:10.1001/jama.2023.5355 · Cited by 148
Self-citationStewart, I. D., Jacob, J., George, P. M., Molyneaux, P. L., Porter, J. C., Allen, R. J., Aslani, S., Baillie, J. K., Barratt, S. L., Beirne, P., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202203-0564oc · Cited by 147
Pardo, A., & Selman, M. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0373ps · Cited by 132
Incidence and predictive factors of lung cancer in patients with idiopathic pulmonary fibrosis
Katô, E., Takayanagi, N., Takaku, Y., Kagiyama, N., Kanauchi, T., Ishiguro, T., & Sugita, Y. (2018) · ERJ Open Research · doi:10.1183/23120541.00111-2016 · Cited by 124
Interstitial Lung Disease in Relatives of Patients with Pulmonary Fibrosis
Hunninghake, G. M., Quesada-Arias, L. D., Carmichael, N. E., Manzano, J. M. M., Poli, S., Baumgartner, M. A., DiGianni, L. M., Gampala-Sagar, S., Leone, D. A., Gulati, S., et al. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201908-1571oc · Cited by 119
Pulmonary Rehabilitation of Interstitial Lung Disease
Ahn, S. Y. (2022) · Annals of CardioPulmonary Rehabilitation · doi:10.53476/acpr.2022.2.1.8 · Cited by 116
Contributions of a hand-held fan to self-management of chronic breathlessness
Luckett, T., Phillips, J. L., Johnson, M. J., Farquhar, M. C., Swan, F., Assen, T., Vandersman, P., & Booth, S. (2017) · European Respiratory Journal · doi:10.1183/13993003.00262-2017 · Cited by 111
Transbronchial Lung Cryobiopsy in Patients with Interstitial Lung Disease: A Systematic Review
Kheir, F. M., Becerra, J. P. U., Bissell, B. D., Ghazipura, M., Herman, D. D., Hon, S. M., Hossain, T., Khor, Y. H., Knight, S. L., Kreuter, M., et al. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202102-198oc · Cited by 107
Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis
Fisher, M., Nathan, S. D., Hill, C., Marshall, J. D., Dejonckheere, F., Thuresson, P.-O., & Maher, T. M. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.3-b.s17 · Cited by 103
Self-citationDiagnosis and Management of Myositis-Associated Lung Disease
Hallowell, R. W., & Danoff, S. K. (2023) · CHEST Journal · doi:10.1016/j.chest.2023.01.031 · Cited by 103
Lung Transplantation for Covid-19–Related Respiratory Failure in the United States
Roach, A., Chikwe, J., Catarino, P., Rampolla, R., Noble, P. W., Megna, D. J., Chen, Q., Emerson, D., Egorova, N., Keshavjee, S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2117024 · Cited by 98
Idiopathic Pulmonary Fibrosis Is Associated with Common Genetic Variants and Limited Rare Variants
Peljto, A. L., Blumhagen, R. Z., Walts, A. D., Cardwell, J., Powers, J., Corte, T. J., Dickinson, J. L., Glaspole, I., Moodley, Y. P., Vašáková, M., et al. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202207-1331oc · Cited by 95
Self-citationZaman, T., Moua, T., Vittinghoff, E., Ryu, J. H., Collard, H. R., & Lee, J. S. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.02.009 · Cited by 89
Martínez, F. J., Yow, E. S., Flaherty, K. R., Snyder, L. D., Durheim, M. T., Wisniewski, S. R., Sciurba, F. C., Raghu, G., Brooks, M. M., Kim, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.4956 · Cited by 89
Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis
Maher, T. M., Costabel, U., Glassberg, M. K., Kondoh, Y., Ogura, T., Scholand, M. B., Kardatzke, D. R., Howard, M., Olsson, J. K., Neighbors, M., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.02442-2019 · Cited by 86
Self-citationAbramson, M. J., Murambadoro, T., Alif, S. M., Benke, G., Dharmage, S. C., Glaspole, I., Hopkins, P. M.-A., Hoy, R. F., Klebe, S., Moodley, Y. P., et al. (2020) · Thorax · doi:10.1136/thoraxjnl-2019-214478 · Cited by 85
Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management
Hallowell, R. W., & Paik, J. J. (2022) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/brvl1v · Cited by 77
Wilson, A. M., Clark, A., Cahn, T., Chilvers, E. R., Fraser, W. D., Hammond, M., Livermore, D. M., Maher, T. M., Parfrey, H., Swart, A. M., et al. (2020) · JAMA · doi:10.1001/jama.2020.22960 · Cited by 75
Self-citationOkada, N., Matsuoka, R., Sakurada, T., Goda, M., Chuma, M., Yagi, K., Zamami, Y., Nishioka, Y., & Ishizawa, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-70743-2 · Cited by 74
Epidemiology of Idiopathic Pulmonary Fibrosis among U.S. Veterans, 2010–2019
Kaul, B., Lee, J. S., Zhang, N., Vittinghoff, E., Sarmiento, K., Collard, H. R., & Whooley, M. A. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202103-295oc · Cited by 74
The prevalence and burden of interstitial lung diseases in the USA
Jeganathan, N., & Sathananthan, M. (2021) · ERJ Open Research · doi:10.1183/23120541.00630-2021 · Cited by 73
Kuwana, M., Gil‐Vila, A., & Selva-O’Callaghan, A. (2021) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x211032457 · Cited by 69
Nalbuphine Tablets for Cough in Patients with Idiopathic Pulmonary Fibrosis
Maher, T. M., Avram, C., Bortey, E., Hart, S. P., Hirani, N., Molyneux, P. L., Porter, J. C., Smith, J. A., & Sciascia, T. R. (2023) · NEJM Evidence · doi:10.1056/evidoa2300083 · Cited by 69
Self-citationPirfenidone in idiopathic pulmonary fibrosis
Maher, T. M. (2010) · Drugs of today · doi:10.1358/dot.2010.46.7.1488336 · Cited by 66
Self-citationBehr, J., Kolb, M. R. J., Song, J. W., Luppi, F., Schinzel, B., Stowasser, S., Quaresma, M., & Martínez, F. J. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201903-0488oc · Cited by 64
Wu, Z., Spencer, L. G., BANYA, W. A. S., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00432-0 · Cited by 64
Lung biopsy in interstitial lung disease: balancing the risk of surgery and diagnostic uncertainty
Cottin, V. (2016) · European Respiratory Journal · doi:10.1183/13993003.01633-2016 · Cited by 57
Salonen, J., Purokivi, M., Bloigu, R., & Kaarteenaho, R. L. (2020) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2020-000563 · Cited by 40
Moran‐Mendoza, O., Ritchie, T., & Aldhaheri, S. (2021) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2020-000815 · Cited by 38
Saunders, P. T., Wu, Z., Fahy, W. A., Stewart, I. D., Saini, G., Smith, D. J. F., Braybrooke, R., Stock, C. J. W., Renzoni, E. A., Johnson, S. R., et al. (2023) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202302-174oc · Cited by 36
Self-citationCommon idiopathic pulmonary fibrosis risk variants are associated with hypersensitivity pneumonitis
Furusawa, H., Peljto, A. L., Walts, A. D., Cardwell, J., Molyneaux, P. L., Lee, J. S., Pérez, E. R. F., Wolters, P. J., Yang, I. V., & Schwartz, D. A. (2022) · Thorax · doi:10.1136/thoraxjnl-2021-217693 · Cited by 34
Myall, K. J., West, A., Martinovic, J. L., Lam, J. L., Roque, D., Wu, Z., Maher, T. M., Molyneaux, P. L., Suh, E., & Kent, B. D. (2023) · CHEST Journal · doi:10.1016/j.chest.2023.05.013 · Cited by 32
Self-citationClubbing in patients with fibrotic interstitial lung diseases
van Manen, M. J. G., Vermeer, L. C., Moor, C. C., Vrijenhoeff, R., Grutters, J. C., Veltkamp, M., & Wijsenbeek, M. S. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.10.021 · Cited by 28
Diagnostic Accuracy of Chest Radiography for Detecting Fibrotic Interstitial Lung Disease
Ghodrati, S., Pugashetti, J. V., Kadoch, M. A., Ghasemiesfe, A., & Oldham, J. M. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202112-1377rl · Cited by 28
Pauchet, A., Chaussavoine, A., Pairon, J. ‐., Gabillon, C., Didier, A. P., Baldi, I., & Esquirol, Y. (2022) · Journal of Toxicology and Environmental Health Part B · doi:10.1080/10937404.2022.2131663 · Cited by 22
Wu, Z., Smith, D. J. F., Yazbeck, L., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202311-2169le · Cited by 21
Use of short-acting opioids in the management of breathlessness: an evidence-based review
Hui, D., & Bruera, E. D. (2020) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000509 · Cited by 20
Kreuter, M., Bendstrup, E. M., Jouneau, S., Maher, T. M., Inoue, Y., Miede, C., Lievens, D., & Crestani, B. (2023) · Respiratory Research · doi:10.1186/s12931-023-02371-z · Cited by 19
Self-citationDempsey, T. M., Thao, V., Helfinstine, D. A., Chang, Y.-H. H., Sangaralingham, L. R., & LIMPER, A. H. (2023) · European Respiratory Journal · doi:10.1183/13993003.01299-2023 · Cited by 16
Metadata
- Authors
- Maher, T. M.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2024-05-21
- Volume
- 331
- Issue
- 19
- Pages
- 1655
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4394997612
- Cited by
- 388
- References
- 103
- FWCI
- 95.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.